The impact of the availability of effective disease-modifying treatment on AD trial design and management
In the US, two anti-amyloid immunotherapies have received accelerated approval for clinical use. Full approval for one or more such therapies is expected within the next year. Trial designs must now adapt to...
- Submission status
- Open
- Submission deadline
- Ongoing